Neurochemical dementia diagnostics in Alzheimer’s disease: where are we now and where are we going?

References

• Mayeux R. Evaluation and use of diagnostic tests in Alzheimer’s disease. Neurobiol. Aging19(2), 139–143 (1998).
   PubMed Web of Science ®Google Scholar
• Klafki HW, Staufenbiel M, Kornhuber J, Wiltfang J. Therapeutic approaches to Alzheimer’s disease. Brain129(Pt 11), 2840–2855 (2006).
   PubMed Web of Science ®Google Scholar
• Reiber H. Dynamics of brain-derived proteins in cerebrospinal fluid. Clin. Chim. Acta310(2), 173–186 (2001).
   PubMed Web of Science ®Google Scholar
• Andreasen N, Minthon L, Davidsson P et al. Evaluation of CSF-Tau and CSF-Aβ42 as diagnostic markers for Alzheimer disease in clinical practice. Arch. Neurol.58(3), 373–379 (2001).
   PubMed Web of Science ®Google Scholar
• Blennow K, Wallin A, Hager O. Low frequency of post-lumbar puncture headache in demented patients. Acta Neurol. Scand.88(3), 221–223 (1993).
   PubMed Web of Science ®Google Scholar
• Weih M, Krinninger M, Zimmermann R et al. [Sensitivity of neurochemical dementia diagnostics in CSF compared to 99mTc-SPECT in Alzheimer‘s dementia]. Fortschr. Neurol. Psychiatr.77(7), 407–411 (2009).
   Google Scholar
• Kang J, Lemaire HG, Unterbeck A et al. The precursor of Alzheimer‘s disease amyloid A4 protein resembles a cell-surface receptor. Nature325(6106), 733–736 (1987).
   PubMed Web of Science ®Google Scholar
• Panegyres PK. The amyloid precursor protein gene: a neuropeptide gene with diverse functions in the central nervous system. Neuropeptides31(6), 523–535 (1997).
   PubMed Web of Science ®Google Scholar
• Klafki H, Abramowski D, Swoboda R, Paganetti PA, Staufenbiel M. The carboxyl termini of β-amyloid peptides 1–40 and 1–42 are generated by distinct γ-secretase activities. J. Biol. Chem.271(45), 28655–28659 (1996).
   PubMed Web of Science ®Google Scholar
• Citron M, Diehl TS, Gordon G, Biere AL, Seubert P, Selkoe DJ. Evidence that the 42- and 40-amino acid forms of amyloid β protein are generated from the β-amyloid precursor protein by different protease activities. Proc. Natl Acad. Sci. USA93(23), 13170–13175 (1996).
   PubMed Web of Science ®Google Scholar
• Lichtenthaler SF, Beher D, Grimm HS et al. The intramembrane cleavage site of the amyloid precursor protein depends on the length of its transmembrane domain. Proc. Natl Acad. Sci. USA99(3), 1365–1370 (2002).
   PubMed Web of Science ®Google Scholar
• Jang H, Arce FT, Ramachandran S et al. Truncated β-amyloid peptide channels provide an alternative mechanism for Alzheimer’s disease and Down syndrome. Proc. Natl Acad. Sci. USA107(14), 6538–6543 (2010).
   PubMed Web of Science ®Google Scholar
• Lewczuk P, Esselmann H, Meyer M et al. The amyloid-β (Aβ) peptide pattern in cerebrospinal fluid in Alzheimer’s disease: evidence of a novel carboxyterminally elongated Aβ peptide. Rapid Commun. Mass Spectrom.17(12), 1291–1296 (2003).
   PubMed Web of Science ®Google Scholar
• Lewczuk P, Esselmann H, Otto M et al. Neurochemical diagnosis of Alzheimer’s dementia by CSF Aβ42, Aβ42/Aβ40 ratio and total Tau. Neurobiol. Aging25(3), 273–281 (2004).
   PubMed Web of Science ®Google Scholar
• Wiltfang J, Esselmann H, Bibl M et al. Highly conserved and disease-specific patterns of carboxyterminally truncated Aβ peptides 1–37/38/39 in addition to 1–40/42 in Alzheimer’s disease and in patients with chronic neuroinflammation. J. Neurochem.81(3), 481–496 (2002).
   PubMed Web of Science ®Google Scholar
• Blennow K, Vanmechelen E, Hampel H. CSF total Tau, Aβ42 and phosphorylated Tau protein as biomarkers for Alzheimer’s disease. Mol. Neurobiol.24(1–3), 87–97 (2001).
   PubMed Web of Science ®Google Scholar
• Wiltfang J, Esselmann H, Maler JM, Bleich S, Hüther G, Kornhuber J. Molecular biology of Alzheimer’s dementia and its clinical relevance to early diagnosis and new therapeutic strategies. Gerontology47(2), 65–71 (2001).
   PubMed Web of Science ®Google Scholar
• Lewczuk P, Wiltfang J. Neurochemical dementia diagnostics: state of the art and research perspectives. Proteomics8(6), 1292–1301 (2008).
   PubMed Web of Science ®Google Scholar
• Motter R, Vigo-Pelfrey C, Kholodenko D et al. Reduction of β-amyloid peptide 42 in the cerebrospinal fluid of patients with Alzheimer’s disease. Ann. Neurol.38(4), 643–648 (1995).
   PubMed Web of Science ®Google Scholar
• Wiltfang J, Esselmann H, Smirnov A et al. β-amyloid peptides in cerebrospinal fluid of patients with Creutzfeldt–Jakob disease. Ann. Neurol.54(2), 263–267 (2003).
   PubMed Web of Science ®Google Scholar
• Sjögren M, Gisslen M, Vanmechelen E, Blennow K. Low cerebrospinal fluid β-amyloid 42 in patients with acute bacterial meningitis and normalization after treatment. Neurosci. Lett.314(1–2), 33–36 (2001).
   PubMed Web of Science ®Google Scholar
• Hulstaert F, Blennow K, Ivanoiu A et al. Improved discrimination of AD patients using β-amyloid(1–42) and Tau levels in CSF. Neurology52(8), 1555–1562 (1999).
   PubMed Web of Science ®Google Scholar
• Galasko D, Chang L, Motter R et al. High cerebrospinal fluid Tau and low amyloid β42 levels in the clinical diagnosis of Alzheimer disease and relation to apolipoprotein E genotype. Arch. Neurol.55(7), 937–945 (1998).
   PubMedGoogle Scholar
• Buee L, Bussiere T, Buee-Scherrer V, Delacourte A, Hof PR. Tau protein isoforms, phosphorylation and role in neurodegenerative disorders. Brain Res. Brain Res. Rev.33(1), 95–130 (2000).
   PubMed Web of Science ®Google Scholar
• Mandelkow E, von Bergen M, Biernat J, Mandelkow EM. Structural principles of Tau and the paired helical filaments of Alzheimer‘s disease. Brain Pathol.17(1), 83–90 (2007).
   PubMed Web of Science ®Google Scholar
• Cairns NJ, Lee VM, Trojanowski JQ. The cytoskeleton in neurodegenerative diseases. J. Pathol.204(4), 438–449 (2004).
   PubMed Web of Science ®Google Scholar
• Shahani N, Brandt R. Functions and malfunctions of the Tau proteins. Cell Mol. Life Sci.59(10), 1668–1680 (2002).
   PubMed Web of Science ®Google Scholar
• Mawal-Dewan M, Henley J, Van de Voorde A, Trojanowski JQ, Lee VM. The phosphorylation state of Tau in the developing rat brain is regulated by phosphoprotein phosphatases. J. Biol. Chem.269(49), 30981–30987 (1994).
   PubMed Web of Science ®Google Scholar
• Rosner H, Rebhan M, Vacun G, Vanmechelen E. Developmental expression of Tau proteins in the chicken and rat brain: rapid down-regulation of a paired helical filament epitope in the rat cerebral cortex coincides with the transition from immature to adult Tau isoforms. Int. J. Dev. Neurosci.13(6), 607–617 (1995).
   PubMed Web of Science ®Google Scholar
• Sunderland T, Linker G, Mirza N et al. Decreased β-amyloid1–42 and increased Tau levels in cerebrospinal fluid of patients with Alzheimer disease. JAMA289(16), 2094–2103 (2003).
   PubMed Web of Science ®Google Scholar
• Otto M, Wiltfang J, Tumani H et al. Elevated levels of Tau-protein in cerebrospinal fluid of patients with Creutzfeldt–Jakob disease. Neurosci. Lett.225(3), 210–212 (1997).
   PubMed Web of Science ®Google Scholar
• Hesse C, Rosengren L, Andreasen N et al. Transient increase in total Tau but not phospho-Tau in human cerebrospinal fluid after acute stroke. Neurosci. Lett.297(3), 187–190 (2001).
   PubMed Web of Science ®Google Scholar
• Iqbal K, Grundke-Iqbal I, Zaidi T et al. Defective brain microtubule assembly in Alzheimer‘s disease. Lancet2(8504), 421–426 (1986).
   PubMed Web of Science ®Google Scholar
• Grundke-Iqbal I, Iqbal K, Tung YC, Quinlan M, Wisniewski HM, Binder LI. Abnormal phosphorylation of the microtubule-associated protein Tau (Tau) in Alzheimer cytoskeletal pathology. Proc. Natl Acad. Sci. USA83(13), 4913–4917 (1986).
   PubMed Web of Science ®Google Scholar
• Hu YY, He SS, Wang X et al. Levels of nonphosphorylated and phosphorylated Tau in cerebrospinal fluid of Alzheimer’s disease patients: an ultrasensitive bienzyme-substrate-recycle enzyme-linked immunosorbent assay. Am. J. Pathol.160(4), 1269–1278 (2002).
   PubMed Web of Science ®Google Scholar
• Iqbal K, Alonso Adel C, El-Akkad E et al. Significance and mechanism of Alzheimer neurofibrillary degeneration and therapeutic targets to inhibit this lesion. J. Mol. Neurosci.19(1–2), 95–99 (2002).
   PubMed Web of Science ®Google Scholar
• Lewczuk P, Esselmann H, Bibl M et al. Tau protein phosphorylated at threonine 181 in CSF as a neurochemical biomarker in Alzheimer’s disease: original data and review of the literature. J. Mol. Neurosci.23(1–2), 115–122 (2004).
   PubMed Web of Science ®Google Scholar
• Vanmechelen E, Van Kerschaver E, Blennow K et al. CSF-phospho-Tau (181P) as a promising marker for discriminating Alzheimer‘s disease from dementia with lewy bodies. In: Alzheimer’s Disease: Advances in Etiology, Pathogenesis and Therapeutics. Iqbal K, Sisodia SS, Winblad B (Eds.) John Wiley and Sons Ltd., Chichester, UK, 285–291 (2001).
   Google Scholar
• Parnetti L, Lanari A, Amici S, Gallai V, Vanmechelen E, Hulstaert F. CSF phosphorylated Tau is a possible marker for discriminating Alzheimer’s disease from dementia with Lewy bodies. Phospho-Tau International Study Group. Neurol. Sci.22(1), 77–78 (2001).
   PubMed Web of Science ®Google Scholar
• Itoh N, Arai H, Urakami K et al. Large-scale, multicenter study of cerebrospinal fluid Tau protein phosphorylated at serine 199 for the antemortem diagnosis of Alzheimer’s disease. Ann. Neurol.50(2), 150–156 (2001).
   PubMed Web of Science ®Google Scholar
• Hampel H, Buerger K, Kohnken R et al. Tracking of Alzheimer‘s disease progression with cerebrospinal fluid Tau protein phosphorylated at threonine 231. Ann. Neurol.49(4), 545–546 (2001).
   PubMed Web of Science ®Google Scholar
• Arai H, Ishiguro K, Ohno H et al. CSF phosphorylated Tau protein and mild cognitive impairment: a prospective study. Exp. Neurol.166(1), 201–203 (2000).
   PubMed Web of Science ®Google Scholar
• Hampel H, Buerger K, Zinkowski R et al. Measurement of phosphorylated Tau epitopes in the differential diagnosis of Alzheimer disease: a comparative cerebrospinal fluid study. Arch. Gen. Psychiatry61(1), 95–102 (2004).
   PubMed Web of Science ®Google Scholar
• Tumani H, Nolker G, Reiber H. Relevance of cerebrospinal fluid variables for early diagnosis of neuroborreliosis. Neurology45(9), 1663–1670 (1995).
   Google Scholar
• Reiber H, Ungefehr S, Jacobi C. The intrathecal, polyspecific and oligoclonal immune response in multiple sclerosis. Mult. Scler.4(3), 111–117 (1998).
   PubMed Web of Science ®Google Scholar
• Wang ZF, Li HL, Li XC et al. Effects of endogenous β-amyloid overproduction on Tau phosphorylation in cell culture. J. Neurochem.98(4), 1167–1175 (2006).
   PubMed Web of Science ®Google Scholar
• Grueninger F, Bohrmann B, Czech C et al. Phosphorylation of Tau at S422 is enhanced by Aβ in TauPS2APP triple transgenic mice. Neurobiol. Dis.37(2), 294–306 (2010).
   PubMed Web of Science ®Google Scholar
• Huang HC, Jiang ZF. Accumulated amyloid-β peptide and hyperphosphorylated Tau protein: relationship and links in Alzheimer’s disease. J. Alzheimers Dis.16(1), 15–27 (2009).
   PubMed Web of Science ®Google Scholar
• Mudher A, Lovestone S. Alzheimer’s disease – do tauists and baptists finally shake hands? Trends Neurosci.25(1), 22–26 (2002).
   PubMed Web of Science ®Google Scholar
• Lewczuk P, Zimmermann R, Wiltfang J, Kornhuber J. Neurochemical dementia diagnostics: a simple algorithm for interpretation of the CSF biomarkers. J. Neural Transm.116(9), 1163–1167 (2009).
   PubMed Web of Science ®Google Scholar
• Lewczuk P, Beck G, Ganslandt O et al. International quality control survey of neurochemical dementia diagnostics. Neurosci. Lett.409(1), 1–4 (2006).
   PubMedGoogle Scholar
• Zetterberg H, Wahlund LO, Blennow K. Cerebrospinal fluid markers for prediction of Alzheimer’s disease. Neurosci. Lett.352(1), 67–69 (2003).
   PubMed Web of Science ®Google Scholar
• Hansson O, Zetterberg H, Buchhave P, Londos E, Blennow K, Minthon L. Association between CSF biomarkers and incipient Alzheimer’s disease in patients with mild cognitive impairment: a follow-up study. Lancet Neurol.5(3), 228–234 (2006).
   PubMed Web of Science ®Google Scholar
• Lewczuk P, Kornhuber J, Vanderstichele H et al. Multiplexed quantification of dementia biomarkers in the CSF of patients with early dementias and MCI: a multicenter study. Neurobiol. Aging29(6), 812–818 (2008).
   PubMedGoogle Scholar
• van Rossum IA, Vos S, Handels R, Visser PJ. Biomarkers as predictors for conversion from mild cognitive impairment to Alzheimer-type dementia: implications for trial design. J. Alzheimers Dis.20(3), 881–891 (2010).
   PubMed Web of Science ®Google Scholar
• Schoonenboom NS, Mulder C, Vanderstichele H et al. Effects of processing and storage conditions on amyloid β (1–42) and Tau concentrations in cerebrospinal fluid: implications for use in clinical practice. Clin. Chem.51(1), 189–195 (2005).
   PubMed Web of Science ®Google Scholar
• Jensen M, Hartmann T, Engvall B et al. Quantification of Alzheimer amyloid β peptides ending at residues 40 and 42 by novel ELISA systems. Mol. Med.6(4), 291–302 (2000).
   PubMed Web of Science ®Google Scholar
• Vanderstichele H, Van Kerschaver E, Hesse C et al. Standardization of measurement of β-amyloid(1–42) in cerebrospinal fluid and plasma. Amyloid7(4), 245–258 (2000).
   PubMed Web of Science ®Google Scholar
• Lewczuk P, Beck G, Esselmann H et al. Effect of sample collection tubes on cerebrospinal fluid concentrations of Tau proteins and amyloid β peptides. Clin. Chem.52(2), 332–334 (2006).
   PubMed Web of Science ®Google Scholar
• Zimmermann R, Lelental N, Ganslandt O, Maler JM, Kornhuber J, Lewczuk P. Preanalytical sample handling and sample stability testing for the neurochemical dementia diagnostics. J. Alzheimer Dis. (In Press) (2011).
   Google Scholar
• Lewczuk P, Kamrowski-Kruck H, Peters O et al. Soluble amyloid precursor proteins in the cerebrospinal fluid as novel potential biomarkers of Alzheimer’s disease: a multicenter study. Mol. Psychiatry15(2), 138–145 (2010).
   PubMed Web of Science ®Google Scholar
• Gabelle A, Roche S, Geny C et al. Correlations between soluble α/β forms of amyloid precursor protein and Aβ38, 40, and 42 in human cerebrospinal fluid. Brain Res.1357, 175–183 (2010).
   Google Scholar
• Felgenhauer K, Beuche W. Labordiagnostik Neurologischer Erkrankungen: Liquoranalytik und -Zytologie, Diagnose- und Processmarker. Thieme, Stuttgart, Germany (1999).
   Google Scholar
• DeMattos RB, Bales KR, Cummins DJ, Dodart JC, Paul SM, Holtzman DM. Peripheral anti-Aβ antibody alters CNS and plasma Aβ clearance and decreases brain Aβ burden in a mouse model of Alzheimer’s disease. Proc. Natl Acad. Sci. USA98(15), 8850–8855 (2001).
   PubMed Web of Science ®Google Scholar
• DeMattos RB, Bales KR, Cummins DJ, Paul SM, Holtzman DM. Brain to plasma amyloid-β efflux: a measure of brain amyloid burden in a mouse model of Alzheimer’s disease. Science295(5563), 2264–2267 (2002).
   PubMed Web of Science ®Google Scholar
• Preston SD, Steart PV, Wilkinson A, Nicoll JA, Weller RO. Capillary and arterial cerebral amyloid angiopathy in Alzheimer’s disease: defining the perivascular route for the elimination of amyloid β from the human brain. Neuropathol. Appl. Neurobiol.29(2), 106–117 (2003).
   PubMed Web of Science ®Google Scholar
• Di Luca M, Pastorino L, Bianchetti A et al. Differential level of platelet amyloid β precursor protein isoforms: an early marker for Alzheimer disease. Arch. Neurol.55(9), 1195–1200 (1998).
   PubMedGoogle Scholar
• Kuo YM, Kokjohn TA, Watson MD et al. Elevated Aβ42 in skeletal muscle of Alzheimer disease patients suggests peripheral alterations of AβPP metabolism. Am. J. Pathol.156(3), 797–805 (2000).
   PubMed Web of Science ®Google Scholar
• van Oijen M, Hofman A, Soares HD, Koudstaal PJ, Breteler MM. Plasma Aβ(1–40) and Aβ(1–42) and the risk of dementia: a prospective case–cohort study. Lancet Neurol.5(8), 655–660 (2006).
   PubMed Web of Science ®Google Scholar
• Mayeux R, Honig LS, Tang MX et al. Plasma Aβ40 and Aβ42 and Alzheimer’s disease: relation to age, mortality, and risk. Neurology61(9), 1185–1190 (2003).
   PubMed Web of Science ®Google Scholar
• Graff-Radford NR, Crook JE, Lucas J et al. Association of low plasma aβ42/aβ40 ratios with increased imminent risk for mild cognitive impairment and Alzheimer disease. Arch. Neurol.64(3), 354–362 (2007).
   PubMedGoogle Scholar
• Sun X, Steffens DC, Au R et al. Amyloid-associated depression: a prodromal depression of Alzheimer disease? Arch. Gen. Psychiatry65(5), 542–550 (2008).
   PubMed Web of Science ®Google Scholar
• Ownby RL, Crocco E, Acevedo A, John V, Loewenstein D. Depression and risk for Alzheimer disease: systematic review, meta-analysis, and metaregression analysis. Arch. Gen. Psychiatry63(5), 530–538 (2006).
   PubMed Web of Science ®Google Scholar
• Lewczuk P, Kornhuber J, Vanmechelen E et al. Amyloid β peptides in plasma in early diagnosis of Alzheimer’s disease: a multicenter study with multiplexing. Exp. Neurol.223(2), 366–370 (2010).
   PubMed Web of Science ®Google Scholar
• Vignali DA. Multiplexed particle-based flow cytometric assays. J. Immunol. Methods243(1–2), 243–255 (2000).
   PubMed Web of Science ®Google Scholar
• Carson RT, Vignali DA. Simultaneous quantitation of 15 cytokines using a multiplexed flow cytometric assay. J. Immunol. Methods227(1–2), 41–52 (1999).
   PubMed Web of Science ®Google Scholar
• Olsson A, Vanderstichele H, Andreasen N et al. Simultaneous measurement of β-amyloid(1–42), total Tau, and phosphorylated Tau (Thr181) in cerebrospinal fluid by the xMAP technology. Clin. Chem.51(2), 336–345 (2005).
   PubMed Web of Science ®Google Scholar
• Richtlinie der Bundesärztekammer zur Qulitätssicherung laboratoriumsmedizinischen Untersuchungen. Deutsches Ärzteblatt105(7), A341–A355 (2008).
   Google Scholar
• Verwey NA, van der Flier WM, Blennow K et al. A worldwide multicentre comparison of assays for cerebrospinal fluid biomarkers in Alzheimer‘s disease. Ann. Clin. Biochem.46(Pt 3), 235–240 (2009).
   PubMed Web of Science ®Google Scholar
• Mattsson N, Blennow K, Zetterberg H. Inter-laboratory variation in cerebrospinal fluid biomarkers for Alzheimer’s disease: united we stand, divided we fall. Clin. Chem. Lab. Med.48(5), 603–607 (2010).
   PubMed Web of Science ®Google Scholar